Acadia Pharmaceuticals | ACAD - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
Acadia Pharmaceuticals USD 146.88M 1.69M 2026-09
ALKERMES USD 190.54M 6.1M 2026-09
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Biogen USD 752M 42.3M 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Cara Therapeutics USD 2.09M 96K 2026-03
Corcept Therapeutics USD 142.04M 14.86M 2026-09
Cytokinetics USD 113.14M 8.75M 2026-09
Eisai JPY 114.83B 4.71B 2026-06
Eli Lilly USD 3.12B 305M 2026-09
Incyte USD 364.27M 12.54M 2026-09
J&J USD 6.25B 168M 2026-09
Moderna USD 282M 66M 2026-09
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Pfizer USD 3.28B 132M 2026-09
Prothena USD 10.9M 1.77M 2026-06
PTC Therapeutics USD 80.63M 6.74M 2026-06
Sarepta Therapeutics USD 118.61M 11.01M 2026-09
Ultragenyx Pharmaceutical USD 97M 9M 2026-09
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09